Gilead Sciences

Gilead Sciences Overview

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Latest News

Aug 1, 2025 · uk.finance.yahoo.com

growth-negative

Stocks to watch next week: BP, Diageo, Disney, Uber and WPP

BP is set to release its second-quarter results amid declining oil and gas prices, with analysts expecting earnings of $1.35 per share and $60 billion in revenue. The company is under pressure due to weak cash flow, rising net debt, and challenges in its transition to cleaner energy sources. Activist investor Elliott has raised concerns over BPs performance, particularly its lagging shareholder returns. Analysts predict a pre-tax profit of $4.6 billion, up from $4.2 billion in Q1, but still below past levels. BPs cash flow and net debt, forecasted to be $24.9 billion by Q1 2025, remain key issues.

Dec 18, 2023 · en.globes.co.il

growth-positive

Compugen signs cancer drug licensing deal with Gilead Sciences

Gilead Sciences has entered into an agreement with Compugen to exclusively license its pre-clinical antibody program targeting IL-18 binding protein. Gilead will make an immediate payment of $60 million to Compugen, with potential milestone payments up to $890 million, excluding royalties. Compugens COM503 drug candidate aims to inhibit cancer growth by releasing natural IL-18 in the tumor microenvironment. Additionally, Compugen will receive a $10 million milestone payment from AstraZeneca for its ARTEMIDE-Bil01 trial. Compugens share price has surged by 156.33% on Nasdaq, reflecting positive market sentiment. The agreement marks a significant step for Compugen in advancing its cancer immunotherapy pipeline.

PartnersInvestment

Aug 28, 2017 · www.calcalist.co.il

growth-positive

אקזיט ענק בביומד הישראלי: גיליד רוכשת את קייט פארמה ב-11.9 מיליארד דולר

Gilead Sciences, a major American pharmaceutical company, has announced its acquisition of Kite Pharma for $11.9 billion in cash, valuing Kite at $180 per share. Kite Pharma, founded by Prof. Arie Belldegrun in 2009, specializes in CAR immunotherapy treatments targeting immune responses for cancer treatment. The acquisition positions Gilead as a leader in cell therapy, with plans to maintain Kites research and development operations in Santa Monica, California. The deal reflects Gileads commitment to advancing innovative cancer treatments and aligns with Kites mission to revolutionize cancer therapy. Major shareholders of Kite include American funds such as Capital Group, BlackRock, and J.P. Morgan.

Acquired-by

Team Members

3

Employees: 11-50

Web & Social Links

Locations

HaHarash St 4, Hod Hasharon, 4524075, Israel

HaHarash St 4, Hod Hasharon, 4524075, Israel

Photos & Videos

No files yet

Gilead Sciences Internal

Recent Updates

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info